Crossline levels in serum and erythrocyte membrane proteins from patients with diabetic nephropathy

被引:10
作者
Aoki, S
Hasegawa, G
Shigeta, H
Obayashi, H
Fujii, M
Kimura, F
Moriwaki, A
Nakamura, N
Ienaga, K
Nakamura, K
Kondo, M
机构
[1] Kyoto Prefectural Univ Med, Dept Internal Med 1, Kyoto 6028566, Japan
[2] Kyoto Microbiol Inst, Dept Clin Res, Kyoto 6078482, Japan
[3] Nippon Zoki Pharmaceut, Inst Bio Act Sci, Kobe, Hyogo, Japan
关键词
diabetic nephropathy; crossline; advanced glycation endproduct;
D O I
10.1016/S0168-8227(99)00148-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Crossline is one of the structurally defined adducts of advanced glycation endproducts (AGEs) which has both a crosslink and fluorescence similar to AGE-protein in vivo. Crossline was measured in serum and erythrocyte membrane proteins (EMP) fi om 52 type 2 diabetic patients using a specific enzyme-linked immunosorbent assay system. Serum and EMP crossline levels in the diabetic patients were significantly higher than those in normal control. The patients with advanced diabetic nephropathy (serum creatinine levels of more than 1.2 mg/dl) had markedly elevated serum crossline levels compared to those with moderate diabetic nephropathy (clinical proteinuria) (180 +/- 51.7 vs. 71.8 +/- 18.4 pmol/ml; P < 0.01). On the other hand, there were no significant differences in EMP crossline levels between the two. EMP crossline levels in the patients with moderate diabetic nephropathy (8.8 +/- 2.9 pmol/mg protein) and those with advanced diabetic nephropathy (9.7 +/- 3.0 pmol/mg protein) were significantly higher than those without clinical proteinuria (6.4 +/- 1.9 pmol/mg protein; P < 0.01). The present study demonstrated that EMP crossline levels were associated with the presence of nephropathy in patients with type 2 diabetes mellitus. Serum crossline levels were significantly influenced by remaining renal function. The measurement of crossline from a blood sample could provide us with important information for the study of clinical evaluation and pathogenesis of diabetic complications. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 21 条
[11]   Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo [J].
Obayashi, H ;
Nakano, K ;
Shigeta, H ;
Yamaguchi, M ;
Yoshimori, K ;
Fukui, M ;
Fujii, M ;
Kitagawa, Y ;
Nakamura, N ;
Nakamura, K ;
Nakazawa, Y ;
Ienaga, K ;
Ohta, M ;
Nishimura, M ;
Fukui, I ;
Kondo, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 226 (01) :37-41
[12]   Glycaemic control and in vivo non-oxidative Maillard reaction: urinary excretion of pyrraline in diabetes patients [J].
PorteroOtin, M ;
Pamplona, R ;
Bellmunt, MJ ;
Bergua, M ;
Prat, J .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1997, 27 (09) :767-773
[13]   QUANTITATION OF LYSINE-BOUND GLUCOSE OF NORMAL AND DIABETIC ERYTHROCYTE-MEMBRANES BY HPLC ANALYSIS OF FUROSINE [EPSILON-N(L-FUROYLMETHYL)-L-LYSINE] [J].
SCHLEICHER, E ;
SCHELLER, L ;
WIELAND, OH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1981, 99 (03) :1011-1019
[14]   Activation of receptor for advanced glycation end products - A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis [J].
Schmidt, AM ;
Yan, SD ;
Wautier, JL ;
Stern, D .
CIRCULATION RESEARCH, 1999, 84 (05) :489-497
[15]  
Sugiyama S, 1998, J AM SOC NEPHROL, V9, P1681
[16]   ADVANCED GLYCOSYLATION ENDPRODUCTS ON ERYTHROCYTE CELL-SURFACE INDUCE RECEPTOR-MEDIATED PHAGOCYTOSIS BY MACROPHAGES - A MODEL FOR TURNOVER OF AGING CELLS [J].
VLASSARA, H ;
VALINSKY, J ;
BROWNLEE, M ;
CERAMI, C ;
NISHIMOTO, S ;
CERAMI, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (02) :539-549
[17]  
VLASSARA H, 1994, LAB INVEST, V70, P138
[18]  
WATALA C, 1985, ANN CLIN RES, V17, P327
[19]   ADVANCED GLYCATION END-PRODUCTS (AGES) ON THE SURFACE OF DIABETIC ERYTHROCYTES BIND TO THE VESSEL WALL VIA A SPECIFIC RECEPTOR INDUCING OXIDANT STRESS IN THE VASCULATURE - A LINK BETWEEN SURFACE-ASSOCIATED AGES AND DIABETIC COMPLICATIONS [J].
WAUTIER, JL ;
WAUTIER, MP ;
SCHMIDT, AM ;
ANDERSON, GM ;
HORI, O ;
ZOUKOURIAN, C ;
CAPRON, L ;
CHAPPEY, O ;
YAN, SD ;
BRETT, J ;
GUILLAUSSEAU, PJ ;
STERN, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) :7742-7746
[20]  
Yamaguchi M, 1998, DIABETIC MED, V15, P458, DOI 10.1002/(SICI)1096-9136(199806)15:6<458::AID-DIA601>3.0.CO